TQ Therapeutics

Executive Summary

TQ Therapeutics is a German biotechnology company founded in 2019 and headquartered in Munich, specializing in the development of safe in vivo cell and gene therapies for challenging diseases. The company's core innovation is the TQx CELLfinity platform, a proprietary EXiVO approach designed to shift away from traditional, costly cell therapy manufacturing toward more efficient and scalable in vivo methods. By leveraging this platform, TQ Therapeutics aims to make curative therapies accessible to a broader patient population. The company operates in the oncology and antibodies categories, reflecting a focus on targeted cancer treatments. As a private entity with limited public information, TQ Therapeutics appears to be in an early stage of development, with potential to disrupt the cell therapy landscape if its platform succeeds in clinical validation.

Upcoming Catalysts (preview)

• 2027Initiation of first-in-human clinical trial for lead candidate50% success
• Q4 2026Preclinical proof-of-concept data release for TQx CELLfinity platform70% success
• Q2 2026Partnership or collaboration with major pharma or CRO40% success